russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLCrussjcardiol-1540Research ArticleКЛИНИКА И ФАРМАКОТЕРАПИЯGUIDELINES FOR THE PRACTITIONERРЕЗУЛЬТАТЫ ТЕРАПИИ СИМВАСТАТИНОМ ЖЕНЩИН В КЛИМАКТЕРИЧЕСКОМ ПЕРИОДЕ С АТЕРОГЕННЫМИ ДИСЛИПОПРОТЕИДЕМИЯМИSimvastatin therapy in climacteric women with atherogenic dyslipoproteinemiasИзможероваН. В.IzmozherovaN. V.ПоповА. А.PopovA. A.Уральская государственная медицинская академия РосздраваRussian Federation200828042008024042Copyright © Изможерова Н.В., Попов А.А., 20082008Изможерова Н.В., Попов А.А.Izmozherova N.V., Popov A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/1540климактерический периодсимвастатинженщинынарушения липидного обменаClimacteric periodsimvastatinwomenlipid metabolism disturbancesReferencesАгеев Ф.Т., Нуралиев Э.Ю., Чернина Г.В. и др. Контролируемое применение симвастатина и «обычная» терапия гиперлипидемии у больных с ишемической болезнью сердца в амбулаторных условиях: сравнительное исследование двух стратегий (СИГНАЛ -КОНТРОЛЬ). Кардиология 2006; 6: 10-15.Агеев Ф.Т., Нуралиев Э.Ю., Чернина Г.В. и др. Контролируемое применение симвастатина и «обычная» терапия гиперлипидемии у больных с ишемической болезнью сердца в амбулаторных условиях: сравнительное исследование двух стратегий (СИГНАЛ -КОНТРОЛЬ). Кардиология 2006; 6: 10-15.Кухарчук В.В., Аронов Д.М., и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации. // Кардиоваскулярная терапия и профилактика. 2004. Т. 3. № S2.Кухарчук В.В., Аронов Д.М., и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации. // Кардиоваскулярная терапия и профилактика. 2004. Т. 3. № S2.Сметник В.П., Кулаков В.И. (ред.). Руководство по климактерию. М.: Медицинское информационное агентство, 2001. 685 с.Сметник В.П., Кулаков В.И. (ред.). Руководство по климактерию. М.: Медицинское информационное агентство, 2001. 685 с.Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360 (9): 7-22.Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360 (9): 7-22.Hully S., Grady D., Bush Т., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605-613.Hully S., Grady D., Bush Т., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605-613.Lemay A., Dodin S., Turcot L., et al. Estrogen/progesterone replacement versus pravastatin and the sequentional association in hypercholesterolemic postmenopausal women. Maturitas 2001; 40: 247-257.Lemay A., Dodin S., Turcot L., et al. Estrogen/progesterone replacement versus pravastatin and the sequentional association in hypercholesterolemic postmenopausal women. Maturitas 2001; 40: 247-257.Ozsener S., Sendag R., Кос Т., et al. A comparison of continuous combined hormone replacement therapy, HMG CoA reductase inhibitor and combined treatment for the management of hypercholesterolemia in postmenopausal women. J Obstet Gynaecol Res 2001; 27: 353-358.Ozsener S., Sendag R., Кос Т., et al. A comparison of continuous combined hormone replacement therapy, HMG CoA reductase inhibitor and combined treatment for the management of hypercholesterolemia in postmenopausal women. J Obstet Gynaecol Res 2001; 27: 353-358.Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.Shepherd J., Packard C., Littlejohn T.W., et al. Lipid-modifying effects of rosuvastatin in postmenopausal women with hypercholesterolemia who are receiving hormone replacement therapy. Curr Med Res Opin 2004; 20 (1): 1571-1578.Shepherd J., Packard C., Littlejohn T.W., et al. Lipid-modifying effects of rosuvastatin in postmenopausal women with hypercholesterolemia who are receiving hormone replacement therapy. Curr Med Res Opin 2004; 20 (1): 1571-1578.Silverman S.L., Delmas P.D., Kulkarni P.M., et al. Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis. J Am Geriatr Soc 2004; 52,(9): 1543-1548.Silverman S.L., Delmas P.D., Kulkarni P.M., et al. Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis. J Am Geriatr Soc 2004; 52,(9): 1543-1548.Tremollieres P.A., Pouilles J-M., Cauneille C. et al. Coronary heart disease risk factors and menopause: a study in 1684 Prench women. Atherosclerosis 1999; 142: 415-423.Tremollieres P.A., Pouilles J-M., Cauneille C. et al. Coronary heart disease risk factors and menopause: a study in 1684 Prench women. Atherosclerosis 1999; 142: 415-423.Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy post-menopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy post-menopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
The authors declare that there are no conflicts of interest present.